As evidenced by studies of breast and pancreatic cancers, inhibition of VEGF/VEGFR2 signaling improved T cell availability at the tumor core with “vascular normalization” and sprouted HEV [146–149]. This evidence concerns the gene VEGFA and neoplasm.